23rd Belgian Congress on Rheumatology · 2019-09-30 · 21.30 Panel Discussion 22.30 End of Day 1...

23rd Belgian Congress on Rheumatology

2 - 4 October 2019

www.rheumacongress.be

Final Programme

3www.rheumacongress.be

Table of Contents

Organisation ...........................................................................................................................4

24th Belgian Congress on Rheumatology - BCR 2020 ..............................................4

Welcome Address ................................................................................................................ 5

Scientific Programme Wednesday, 2 October .............................................................. 6

Scientific Programme Thursday, 3 October ................................................................... 9

Scientific Programme Friday, 4 October ....................................................................... 12

Meeting for Health Professionals in Rheumatology ................................................... 14

Registration ........................................................................................................................... 16

General Information ............................................................................................................ 17

Major Sponsors & Exhibitors ............................................................................................21

4 5www.rheumacongress.be www.rheumacongress.be

Organisation

Scientific Organiser Maria StoenoiuCliniques universitaires Saint-Luc Avenue Hippocrate 10, 1200 Bruxelles [email protected]

Local Organising Committee Veerle TaelmanUZ LeuvenHerestraat 49, 3000 [email protected]

Margot Van MechelenUZ LeuvenHerestraat 49, 3000 [email protected]

René WesthovensUZ LeuvenHerestraat 49, 3000 [email protected]

Upcoming Congress24th Belgian Congress on Rheumatology - BCR 2020 23 - 25 September 2020Mons International Congress Xperience

Congress Secretariat Medicongress Services Noorwegenstraat 49 B-9940 Evergem, Belgium Phone: +32 (0)9 218 85 8Fax: +32 (0)9 344 40 10 [email protected] www.medicongress.com

M E D I C O N G R E S S

Welcome Address

Dear colleagues and friends,

The Royal Belgian Society for Rheumatology takes great pleasure in welcoming you to the 23rd Belgian Congress on Rheumatology, taking place in Leuven on 2- 4 October 2019.

The congress takes place at the University Hall of the KU Leuven. The Hall was originally built by the weavers to be used for trading fabric. The Fabric Hall is currently the central place for student enrolment.

We are proud to propose a varied and interesting programme with state-of-the-art keynote lectures and oral communications. The ‘Year in Review’ will also be presented again, providing you with a survey of the Belgian publications of the last year.

Furthermore, 2 poster tours, 4 workshops for early risers and 12 Updates in Therapeutics are scheduled. The ‘Thieves Market’ is also scheduled again this year.

Together with the KBVR-SRBR Board members, we hope you will enjoy the Congress and the city of Leuven and remain,

Yours sincerely,

Prof. Maria StoenoiuScientific Organiser

Veerle Taelman, Margot Van Mechelen, René Westhovens Local Organising Committee


Wednesday, 2 October Young Investigator Meeting Promotiezaal Chairs: Olivier Malaise (CHU de Liège, ULg) and Rik Lories (KU Leuven)

10.00 Absence of MALT1 in T-cells protects against the development of auto- immune arthritis, but indirectly causes osteoporosis Elisabeth Gilis (UGent)

10.15 Detection of multiple myositis-specific autoantibodies with line and dot immunoassays in patients with idiopathic inflammatory myopathies Jean-Baptiste Vulsteke (KU Leuven)

10.30 High disease activity impairs work participation and work productivity in spondyloarthritis patients Ann-Sophie De Craemer (UGent)

10.45 Generation of an inducible tissue-specific DIO2 overexpression mouse Frederique Cornelis (KU Leuven)

11.00 Inhibition of Sphingosine 1 Phosphate protects chondrocyte catabolism and osteoarthritis Chahrazad Cherifi (KU Leuven)

11.15 Hyperosmolar stress-induced osmoadaptative and inflammatory responses in human salivary glands cells Clara Chivasso (ULB)

11.30 Identification of transcription factors and networks regulating the DOT1L gene Astrid De Roover (KU Leuven) 11.45 ANP32A deficiency partially protects against bleomycin-induced skin fibrosis Nathalie Berghen (KU Leuven)

12.00 Welcome Lunch in the Exhibition Hall

Wednesday, 2 October 12.30 Opening Ceremony Promotiezaal Maria Stoenoiu, Scientific Organiser, Dirk Elewaut and Catherine Bailleux, KBVR-SRBR

SESSION 1 Promotiezaal Chairs: Pascale Volders (ReumaClinic Genk) and Patrick Verschueren (KU Leuven)

12.50 Vesalius Lecture Outcome measures in rheumatology, from trial to practice - How out come measures have transformed rheumatology Maarten Boers (The Netherlands)

Abstract Presentations

13.35 Seroreversion of autoantibodies to UH-RA.21 peptide is associated with CDAI remission in rheumatoid arthritis patients of the CareRA cohort Patrick Vandormael (Hasselt University)

13.45 Comparison of transcriptomic profiles between paired joint biopsies from Rheumatoid Arthritis patients Clément Triaille (UCL)

13.55 Enrichment of RORγt+ innate-like T cells in joint and gut samples from spondyloarthritis patients Céline Mortier (UGent)

14.05 FWRO/FRSR Award Ceremony René Westhovens (KU Leuven) and Philippe Carron (UGent)

14.30 Update in Therapeutics – Organised with an educational grant from Sanofi Why does clinical practice not always reflect clinical guidelines? Robert Landewé (The Netherlands)

15.00 Update in Therapeutics – Organised with an educational grant from Amgen The value of treatment monitoring and targeting in chronic rheumatic diseases Tore Kvien (Norway)

15.30 Coffee Break in the Exhibition Hall


Wednesday, 2 October

SESSION 2 Promotiezaal Chairs: Alla Ishchenko Alla Ishchenko (ZNA Jan Palfijn, Middelheim Hospital, UZ Gasthuisberg, KU Leuven) and Kurt de Vlam (KU Leuven)

16.00 Treatment of Sjogren’s disease – State-of-the-Art Isabelle Peene (AZ Sint-Jan)

16.30 The hunt for the wolf: Shaping the treatment of SLE Farah Tamirou (UCL)

17.00 Update in Therapeutics – Organised with an educational grant from RocheRituximab in auto-immune diseases

Ellen De Langhe (KU Leuven) 17.30 Update in Therapeutics – Organised with an educational grant from AbbVie

Comorbidities management in spondyloarthritis Anna Molto (France) 18.00 Walking Dinner in the Exhibition Hall

SESSION 3 - Ethics & Economy Promotiezaal Chairs: Margot van Mechelen (KU Leuven), Veerle Taelman (KU Leuven) and René Westhovens (KU Leuven)

19.30 Health professionals: Current and future projects Overview of the organization of Belgium’s healthcare Caroline Teugels, International Federation of Podiatrists

19.45 Patient associations: Current and future activities How to increase visibility and awareness Gerd Jacobs, ReumaNet and Alain Cornet, CLAIR

20.00 BRV-AMRB update and future projects - Organisation of healthcare in Belgium Laurent Méric de Bellefon (CNDG, CHU Saint-Pierre Brussels, UCL) and Ilse Hoffman (GZA, AZ Sint Jozef)

20.30 The bionic patient: Consumer technology including wearables changing clinical practice Will Dixon (United Kingdom) and Thijs Swinnen (KU Leuven)

21.30 Panel Discussion

22.30 End of Day 1

Thursday, 3 October

08.00 Workshop 1 Room Franciscanen Evaluation and management of psoriatic arthritis and psoriasis Kurt de Vlam (KU Leuven) and Adrien Nzeusseu Toukap (UCL)

Workshop 2 Room Dominicanen Autoantibodies in clinical practice Ellen De Langhe (KU Leuven) and Xavier Bossuyt (KU Leuven)

The Workshops take place at Hotel Martin’s Klooster, O.L.Vrouwstraat 18 (located at 450 m from the University Hall).

SESSION 4 Promotiezaal Chairs: Silvana Di Romana (CHU St. Pierre) and Vanessa Smith (UGent)


09.00 Maintaining remission in patients with rheumatoid arthritis while tapering etanercept: The TapERA trial Delphine Bertrand (KU Leuven)

09.10 Fast Track algorithm: How to differentiate a ‘scleroderma pattern’ from a ‘non-scleroderma’ pattern Vanessa Smith (UGent)

09.20 First data of the TARDIS-RA registry, a nationwide Belgian Biologic registry Diederik De Cock (KU Leuven)

09.30 Cardiovascular comorbidities in rheumatic diseases Anne Grete Semb (Norway)

10.15 Year in Review – Clinical and basic science Béatrice André (CHU de Liège, ULg) and Shan Soyfoo (ULB)


11.00 Poster Tour 1 in the Exhibition Hall Poster Tour Leaders: Peggy Jacques (UGent) and Patrick Verschueren (KU Leuven) Poster presenters are invited to be available for Q&A


Thursday, 3 October

SESSION 5 Promotiezaal Chairs: Charline Rinkin (CHU de Liège, ULg) and Rik Lories (KU Leuven)

11.30 Update in Therapeutics – Organised with an educational grant from Eli Lilly Small molecules will change rheumatology - Update on JAKs/kinase inhibition

Daniel Aletaha (Germany)

12.00 Update in Therapeutics – Organised with an educational grant from BMSBiomarkers: What can we learn from immuno-oncology?Karim Vermaelen (UGent)

12.30 SpA: State-of-the-art diagnosis and treatment of peripheral spondyloarthritis - Worth the attention? Philippe Carron (UGent)

13.00 Lunch in the Exhibition Hall

14.00 General Assembly

SESSION 6 Promotiezaal Chairs: Maria-José Fernandez (UZA, Medicis, OLV Aalst) and Ruth Wittoek (UGent, ZNA Jan Palfijn)

14.15 Update in Therapeutics – Organised with an educational grant from MSDImaging in the diagnosis and treatment of axial spondylarthropathiesXenofon Baraliakos (Germany)

14.45 Update in Therapeutics – Organised with an educational grant from Biogen How should biosimilars be used to treat rheumatic diseases?Alfons den Broeder (The Netherlands)

15.15 The power and pitfalls of musculoskeletal ultrasound in daily practice Maria Stoenoiu (UCL)


Thursday, 3 October

SESSION 7 Promotiezaal Chairs: Laure Tant (ULB) and Filip Van den Bosch (UGent)


16.20 Predictors of radiographic progression in hand osteoarthritis: A ten-years prospective cohort study Tine Vanhaverbeke (UGent)

16.30 Predictors of functional progression in hand osteoarthritis: A ten-years prospective cohort study Lisa Pardaens (UGent)

16.40 In-hospital screening is more effective than ambulatory practice screening to detect osteoporosis: A 6-year study in 6406 patients Olivier Malaise (ULg)

16.50 Update in Therapeutics – Organised with an educational grant from Novartis

New insights in the pathogenesis of spondyloarthritisDirk Elewaut (UGent)

17.20 Update in Therapeutics – Organised with an educational grant from Galapagos

How digital technologies enable the global transformation of healthcare Geert Reyniers (Duval Union Consulting)

17.50 End of Day 2


Friday, 4 October

08.00 Workshop 3 Room Dominicanen Ultrasound hands-on: Ankle Philippe Carron (UGent), Alla Ishchenko (ZNA Jan Palfijn, Middelheim Hospital, UZ Gasthuisberg, KU Leuven), Maria-José Fernandez (UZA, Medicis, OLV Aalst), Marie Joelle Kaiser (Ulg), Ruth Wittoek (UGent, ZNA Jan Palfijn), Maria Stoenoiu (UCL)

Workshop 4 Room Predikheren Axial MRI interpretation Lennart Jans and Peggy Jacques (UGent)

The Workshops take place at Hotel Martin’s Klooster, O.L.Vrouwstraat 18 (located at 450 m from the University Hall).

SESSION 8 Promotiezaal Chairs: Olivier Malaise (CHU de Liège, ULg) and Ilse Hoffman (GZA Sint-Augustinus, Wilrijk)

09.00 The future treatments of OA Rik Lories (KU Leuven)


09.30 Gender contrasts in patient reported outcomes do not alter the disease activity score in axial spondyloarthritis patients Ann-Sophie De Craemer (UGent)

09.40 High prevalence of sacroiliac bone marrow edema on MRI in postpartum women: A temporary phenomenon Thomas Renson (UGent)

09.50 ANP32A is a hub molecule regulating a protective network against osteoarthritis Silvia Monteagudo (KU Leuven)

10.00 Update in Therapeutics – Organised with an educational grant from Celgene Management of psoriatic arthritis from the view of the dermatologist Diamant Thaçi (Germany)

10.30 Update in Therapeutics – Organised with an educational grant from Pfizer Pain and other outcomes in patients treated with JAK/STAT inhibitors Ernest Choy (United Kingdom)

Friday, 4 October


11.15 Poster Tour 2 in the Exhibition Hall Poster Tour Leaders: Silvia Monteagudo (KU Leuven) and Olivier Malaise (CHU de Liège, ULg) Poster presenters are invited to be available for Q&A

11.45 Bone and Joint Lecture Promotiezaal Rheumatoid arthritis, yesterday and tomorrow René Westhovens (KU Leuven)

SESSION 9 Promotiezaal Chairs: Bouchra Lechkar (UZA) and Xavier Janssens (AZ Sint-Lucas, UGent)

Thieves Market

12.15 A novel phenotype of adult-onset autoinflammatory syndrome caused by somatic NLRC4 mosaicism Nathalie Berghen (KU Leuven)

12.25 Fulminant macrophage activation syndrome in a patient with anti- synthetase syndrome successfully treated with etoposide Friedel Vulsteke (KU Leuven)

12.35 Multiple vertebral fractures after bone marrow transplantation in a young patient with sickle cell disease? When DEXA misleads us Marine Mina (ULg)

12.45 Closure of the Congress

13.00 Farewell Lunch

13.45 KBVR-SRBR Board Meeting Room Predikheren,Hotel Martin’s Klooster


Thursday, 3 October

Meeting for Health Professionals in Rheumatology – Morning Chairpersons: Kristien Van der Elst ( UZ Leuven) and Elli Sydow (UZ Leuven)

08.30 Registration*

09.00 Welcome Karlien Claes, MSc rheumatology nurse, Ghent University Hospital President of the Belgian Health Professionals in Rheumatology

A peek into the everyday life of children and young people with rheumatic conditions

09.10 Juvenile rheumatic diseases and therapies Joke Dehoorne, PhD, pediatrician, department of Rheumatology, Sint-Elisabeth Hospital/Ghent University Hospital Lien De Somer, PhD, pediatrician, department of Rheumatology, University Hospital Leuven

09.45 What does it mean to grow up with juvenile idiopathic arthritis? A patient’s view

10.00 Young people in pediatric and adult rheumatology: Who cares? Margot Walter, PhD, Nurse specialist in Rheumatology, Erasmus MC, Rotterdam

10.30 Coffee break

Chairpersons: Aleksandra Avramosvka (UC Louvain) and Karlien Claes (Ghent University Hospital)

11.00 How to treat locomotor impairments in children with a rheumatic disease? Ruth Van der Looven, MD, PhD, physiatrist, department of physical medicine and child rehabilitation, Ghent University Hospital

11.30 What is the added value of a psychologist in the management of children with JIA Joanna Willen, psychologist, University Hospital Leuven

12.00 What does it mean to grow up with juvenile idiopathic arthritis? A patient’s view

12.15 Lunch Break & Networking

*Registration includes coffee breaks and lunch.

Thursday, 3 October

Meeting for Health Professionals in Rheumatology – Afternoon

13.30 General Assembly BeHPR Welcome and a must-do for all

Chairpersons: Laura Lepers (Erasme ULB) and Chantal Robert (Erasme ULB)

14.20 New insights in the management of Spondylarthropathy Adrien Nzeusseu, Prof. Dr., Rheumatology department, St-Luc University hospital, Experimental and Clinical Research Institutes, UC Louvain, Brussels

14.40 Belgian Inflammatory Arthritis and Spondylitis Cohorte (Be-Giant) Thomas Renson, PhD candidate, pediatrician, department of Rheumatology, Sint-Elisabeth Hospital/ Ghent University Hospital

15.00 Abstract 1: A mixed method study to explore the feasibility and patient satisfaction of two different exercise programs in systemic sclerosis associated microstomia Ellinor Sydow, MSc Occupational therapist, University Hospital Leuven

15.10 Coffee break

Chairpersons: Caroline Teugels (Executive Director of the International Federation of Podiatrists) and Karlien Claes (Ghent University Hospital)

15.40 Abstract 2: Why doing "CardioPulmonaryExerciseTesting" for Rheumatoid Arthritis patients is important Chantal Robert, physiotherapist, University Hospital Brussels

15.50 The added value of a physiotherapist in people with a rheumatic disorder Dieter Van Assche, Physical therapist at division of rheumatology University Hospitals Leuven and assistant professor at department of rehabilitation sciences KU Leuven

16.20 Workshop: The benefits of a good sport shoe 16.50 Closing

The Meeting for Health Professionals in Rheumatology takes place at Room Predikheren, Hotel Martin’s Klooster.


Registration

Registration Fees LATE As of 1 SeptemberMembers KBVR-SRBR € 250,00Non Members € 350,00 Trainees in Rheumatology* € 75,00 Other Trainees* € 100,00 Researchers non-MD* € 75,00 Emeriti € 75,00

Workshops** Free

Healthcare Professionals Meeting Freeon Thursday 03/10

* Registration as a trainee or researcher non-MD will only be accepted if accompanied by a copy of your student card or a certificate of your director. Without proof the non-member fee will be charged.** Participation in the workshops is free of charge and is limited to 30 participants.

The registration fee for participants includes• Participation in all scientific sessions• Participation in the hands-on workshops (separate registration required,

limited to 30 participants)• Participation in the ‘Updates in Therapeutics’ organised by the Industry• Congress bag with the Programme and Abstracts and congress related

documents• Access to the exhibition• Lunches and coffee breaks

CancellationsParticipants canceling their registration before 1 September 2019, will receive a full refund, less € 50,00 administration costs. There will be no refunds for cancellations received after this date. Cancellations must be confirmed in writing to the Organising Secretariat. All refunds will be processed after the Congress.

General Information

Venues University Hall KU Leuven Naamsestraat 223000 Leuen

The Workshops take place in at Hotel Martin’s Klooster, O.L.Vrouwstraat 18 (located at 450 m from the Universiteitshallen).

Accreditation A request for accreditation has been submitted to the RIZIV/INAMI. A certificate of attendance will be sent by email after the Congress. Please make sure to sign the attendance list each day at the KBVR-SRBR booth.

Exhibition A medical exhibition will be held on the occasion of the Congress. Access is free for registered participants. The exhibition is not accessible for non-MDs.

Liability Neither the organisers nor Medicongress accept liability for damages and/or losses of any kind which may be incurred by Congress participants during the Congress. Participants are advised to take out insurance against loss, accidents or damage which could be incurred during the Congress.


Notes Notes


Major SponsorsNotes

The Organising Committee of the 23rd Belgian Congress on Rheumatology would like to thank

Major Sponsors

AbbVie

Amgen

Biogen Belgium

Bristol-Myers Squibb

Celgene

Eli Lilly

Galapagos

MSD Belgium

Novartis Pharma

Pfizer

Roche

Sanofi

Exhibitors

AbbVie

BK Medical Benelux

Fresenius-Kabi

GE Healthcare

Grünenthal

Lamepro

Mylan

Tilman

TRB Chemedica

UCB Pharma

Sandoz_1909_adv_A5.indd 1 09/09/2019 16:36

WATCH MEIMPROVE AND MOVE MOBILITY TODAY

AND TOMORROW

▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See full leaflet for how to report adverse reactions. Name: Cosentyx 150 mg solution for injection in pre-filled syringe / Cosentyx 150 mg solution for injection in pre-filled pen Composition: Each pre-filled syringe contains 150 mg secukinumab* in 1 ml / Each pre-filled pen contains 150 mg secukinumab* in 1 ml. * Secukinumab is a recombinant fully human monoclonal antibody selective for interleukin-17A. Secukinumab is of the IgG1/κ-class produced in Chinese Hamster Ovary (CHO) cells. For the full list of excipients, see full leaflet. Pharmaceutical form: Solution for injection in pre-filled syringe (injection). The solution is clear and colourless to slightly yellow / Solution for injection in pre-filled pen (SensoReady pen). The solution is clear and colourless to slightly yellow. Therapeutic indications: Plaque psoriasis: Cosentyx is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. Psoriatic arthritis: Cosentyx, alone or in combination with methotrexate (MTX), is indicated for the treatment of active psoriatic arthritis in adult patients when the response to previous disease-modifying anti-rheumatic drug (DMARD) therapy has been inadequate. Ankylosing spondylitis: Cosentyx is indicated for the treatment of active ankylosing spondylitis in adults who have responded inadequately to conventional therapy. Posology: Cosentyx is intended for use under the guidance and supervision of a physician experienced in the diagnosis and treatment of conditions for which Cosentyx is indicated. Plaque psoriasis. The recommended dose is 300 mg of secukinumab by subcutaneous injection with initial dosing at Weeks 0, 1, 2, 3 and 4, followed by monthly maintenance dosing. Each 300 mg dose is given as two subcutaneous injections of 150 mg. Psoriatic arthritis. For patients with concomitant moderate to severe plaque psoriasis or who are anti-TNFα inadequate responders (IR), the recommended dose is 300 mg by subcutaneous injection with initial dosing at Weeks 0, 1, 2, 3 and 4, followed by monthly maintenance dosing. Each 300 mg dose is given as two subcutaneous injections of 150 mg.For other patients, the recommended dose is 150 mg by subcutaneous injection with initial dosing at Weeks 0, 1, 2, 3 and 4, followed by monthly maintenance dosing. Based on clinical response, the dose can be increased to 300 mg. Ankylosing spondylitis. The recommended dose is 150 mg by subcutaneous injection with initial dosing at Weeks 0, 1, 2, 3 and 4, followed by monthly maintenance dosing. For all of the above indications, available data suggest that a clinical response is usually achieved within 16 weeks of treatment. Consideration should be given to discontinuing treatment in patients who have shown no response by 16 weeks of treatment. Some patients with an initial partial response may subsequently improve with continued treatment beyond 16 weeks. Special populations: Elderly patients (aged 65 years and over): No dose adjustment is required. Renal impairment / hepatic impairment: Cosentyx has not been studied in these patient populations. No dose recommendations can be made. Paedriatic population: The safety and efficacy of Cosentyx in children below the age of 18 years have not yet been established. No data are available. Contraindications: Severe hypersensitivity reactions to the active substance or to any of the excipients. Clinically important, active infection (e.g. active tuberculosis). Undesirable effects: Summary of the safety profile: see full leaflet. List of adverse reactions: ADRs from psoriasis, psoriatic arthritis and ankylosing spondylitis clinical studies as well as from post-marketing experience (Table 1) are listed by MedDRA system organ class. Within each system organ class, the ADRs are ranked by frequency, with the most frequent reactions first. Within each frequency grouping, adverse drug reactions are presented in order of decreasing seriousness. In addition, the corresponding frequency category for each adverse drug reaction is based on the following convention: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000); and not known (cannot be estimated from the available data).List of adverse reactions in clinical studies1) and post-marketing experience: Infections and infestations: Very common: Upper respiratory tract infections; Common: Oral herpes; Uncommon: Oral candidiasis; Uncommon: Tinea pedis; Uncommon: Otitis externa. Not known: Mucosal and cutaneous candidiasis (including oesophageal candidiasis). Blood and lymphatic system disorders: Uncommon: Neutropenia. Immune system disorder: Rare: Anaphylactic reactions. Eye disorders: Uncommon: Conjunctivitis. Respiratory, thoracic and mediastinal disorders: Common: Rhinorrhoea. Gastrointestinal disorders: Common: Diarrhoea. Skin and subcutaneous tissue disorders: Uncommon: Urticaria. 1)Placebo-controlled clinical studies (phase III) in plaque psoriasis, PsA and AS patients exposed to 300 mg, 150 mg or placebo up to 12 weeks (psoriasis) or 16 weeks (PsA and AS) treatment duration. Description of selected adverse reactions: see full leaflet. Reporting of suspected adverse reactions: Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system. Mode of delivery: Medicinal product subject to medical prescription. Marketing authorisation holder and numbers: Novartis Europharm Limited, Vista Building, Elm Park, Merrion Road, Dublin 4, Ireland; EU/1/14/980/001- EU/1/14/980/007 Date of revision of the text: 23.10.2018

* ordinary insured persons (preferentially insured persons € 8,00)

P.P. Co-payment*Cosentyx® 2x150 mg € 1.059,78 € 12,10 Cosentyx® 1x150 mg € 565,09 € 12,10

FOR ANKYLOSING SPONDYLITIS AND PSORIATIC ARTHRITIS

BE1903986436-26/03/2019

Cosentyx_SpA_Pub_A5.indd 1 20/09/2019 9:56:27

Date post:	23-Apr-2020
Category:	Documents
Upload:	others
View:	2 times
Download:	0 times

23rd Belgian Congress on Rheumatology · 2019-09-30 · 21.30 Panel Discussion 22.30 End of Day 1...

Documents